Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception

Area of Science:

• Pharmaceutical Sciences
• Regulatory Affairs
• Pharmacokinetics

Background:

• Generic pharmaceuticals require rigorous bioequivalence testing.
• Current regulations may not fully address stereoselective aspects of generic APIs.
• Understanding racemic product performance is vital for market approval.

Purpose of the Study:

• To highlight the importance of regulatory aspects and pharmacopoeias in bioequivalence investigations.
• To emphasize the need for stereoselective bioequivalence evaluation of generic pharmaceuticals.
• To address the performance of racemic generic products in the market.

Main Methods:

• Literature review encompassing USP monographs, FDA requirements, and international guidelines.
• Searches conducted through various databases including PubMed, PubMed Central, and WHO Drug Information.
• Analysis of published data on generic Active Pharmaceutical Ingredients (APIs) and pharmaceutical inspections.

Main Results:

• Bioequivalence studies and regulatory requirements (USP, FDA) for generic APIs were examined.
• Examples of concerns regarding pharmaceutical import/export inspections were identified.
• The need for stereoselective investigations was highlighted based on literature and regulatory standards.

Conclusions:

• The United States Pharmacopeia (USP), US Food and Drug Administration (USFDA), and international bodies should enforce stereoselective investigations for generic APIs.
• Pharmaceutical companies must demonstrate equivalent PK/PD parameters for racemic generic products compared to standards.
• Global enforcement of these regulations is essential for patient care and pharmaceutical trade.